Share on StockTwits

Shire PLC (LON: SHP) was the recipient of a ratings changes during the seven days:

  • Shire PLC had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a GBX 3,700 ($63.46) price target on the stock.
  • Shire PLC had its price target raised by analysts at Cenkos Securities Ltd from GBX 4,005 ($68.70) to GBX 5,200 ($89.19). They now have a “buy” rating on the stock.
  • Shire PLC had its “outperform” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 3,600 ($61.75) price target on the stock.
  • Shire PLC had its “neutral” rating reaffirmed by analysts at Credit Suisse. They now have a GBX 4,200 ($72.04) price target on the stock.
  • Shire PLC had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 5,300 ($90.91) price target on the stock, up previously from GBX 4,626 ($79.35).
  • Shire PLC had its “overweight” rating reaffirmed by analysts at Barclays.
  • Shire PLC had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a GBX 3,700 ($63.46) price target on the stock.

Shire PLC (LON:SHP) opened at 4600.00 on Friday. Shire PLC has a one year low of GBX 2175.00 and a one year high of GBX 4925.00. The stock has a 50-day moving average of GBX 3925.16 and a 200-day moving average of GBX 3315.11. The company’s market cap is £26.878 billion.

Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.